XWXinru Wang

Xinru Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinru Wang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Dexiong Han

    The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, 310053 Hangzhou, Zhejiang, China

    1 shared publication
  • Hantong Hu

    Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University

    1 shared publication
  • Huifeng Dai

    Department of Acupuncture and Moxibustion, Changxing County Traditional Chinese Medicine Hospital, Huzhou, Zhejiang, People’s Republic of China

    1 shared publication
  • Jiajun Shentu

    Department of Acupuncture and Moxibustion, Hangzhou Third People’s Hospital, Hangzhou, Zhejiang, People’s Republic of China

    1 shared publication
  • Jiaqi Wu

    The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China

    1 shared publication
  • Kelin He

    Key Laboratory of Acupuncture and Neurology of Zhejiang Province, The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Efficacy and Safety of Electroacupuncture for Postherpetic Neuralgia and Biomarker Evaluation: A Study Protocol for a Multicenter, Randomized Trial

    by Qintao Yu, Xinru Wang, Jiaqi Wu, Qiyuan Zhang, Xiaoqi Ying, Liming Ou, Hantong Hu, Kelin He, Lei Wu, Zongda Jin, et al.

    Introduction: Postherpetic neuralgia (PHN) is a persistent neuropathic pain condition that endures for at least 3 months following the onset of herpes zoster, significantly impairing life quality of patients. Current PHN treatments demonstrate limited efficacy, and the lack of reliable severity biomarkers hinders effective clinical management. Electroacupuncture represents a promising therapeutic approach for PHN, though comprehensive evidence supporting its efficacy and safety is still needed. Furthermore, as objective indicators, the role of serum biomarkers in assessments still requires further investigation. Methods: This multicenter, sham-controlled, randomized study will recruit 180 patients with PHN. Participants will be allocated in a 1:1:1 ratio to electroacupuncture, sham acupuncture, or waiting-list groups via multicenter stratified block randomization. Participants will receive 1-month of treatment and 3-month follow-ups. The electroacupuncture group and the sham acupuncture group will each receive 12 treatments. All participants will maintain their pre-enrollment medication. Primary outcome is Numerical Rating Scale; secondary outcomes include pain episode frequency, Hamilton Anxiety Scale, Hamilton Depression Scale, The Short-Form 36 Health Survey, and changes of biomarkers (Neuropeptide Y, Substance P, Tumor Necrosis Factor-α, Interleukin-10). A linear mixed-effects model will be used to analyze data at different time points to explore the efficacy of electroacupuncture and the correlation between serum biomarkers and pain intensity. The predictive value of biomarkers for refractory postherpetic neuralgia (NRS reduction < 30% from baseline post-treatment) will be assessed using ROC curves. Conclusion: The expected outcomes will clarify the efficacy and safety of electroacupuncture for PHN. The study will also analyze the correlation between serum biomarkers and pain symptoms and determine whether serum biomarkers can serve as prognostic indicators for refractory postherpetic neuralgia. Trial Registration: ClinicalTrials.gov identifier: NCT06990854. Registered on June 3, 2025. (https://clinicaltrials.gov/study/NCT06990854).